In addition to the tumor-intrinsic cytotoxicity of PARP inhibitors attributed to synthetic lethality with homologous recombination repair deficiency and PARP trapping2–4,22, PARP inhibition has been suggested by emerging evidence to modify the immune context of tumors11,17,18,23. The gene discussed is PARP1; the disease is neoplasm.